Andrew Raubitschek, MD
Articles
Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas
December 1st 1998The article by Dr. McLaughlin and coauthors provides both a useful summary of the clinical trials involving rituximab (IDEC C2B8 [Rituxan]) and a practical guide for its administration. Their review summarizes the most recent clinical results with this monoclonal antibody, which have just been published in the Journal of Clinical Oncology.[1] The review also includes a section on the potential mechanism of action of rituximab. Several areas merit comment.
Latest Updated Articles
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: August 19th 2019 | Updated: November 21st 2024
A 22-Year-Old Woman With Pain, Tenderness and Swelling in the Breast
Published: July 29th 2015 | Updated: November 21st 2024
Liver Abnormality in 28-Year-Old Patient
Published: November 8th 2024 | Updated: November 21st 2024
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
